Teva Pharmaceutical Industries (TEVA) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

ProductDistribution ServiceLicenseProduct and Service, Other
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

United States SegmentEurope SegmentNorth America Segment
0875M2B3B4B4B5B6B7BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
01B2B4B5B6B8B9B10BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
012253850627588100Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-20-16-13-9-6-2259Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
048111519222630Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0918263544526170Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeTotal Other Income Expenses NetNet Income
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
012344567Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
0625M1B2B2B3B4B4B5BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics